French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, ...

The panel also said Beyfortus (nirsevimab) could be an option for ... the regulator's Antimicrobial Drugs Advisory Committee, and Sanofi confirmed that it will be launched ahead of the 2023-2024 ...

AstraZeneca and Sanofi have secured approval in the ... It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

In the meantime, Sanofi remains “very confident” in the Beyfortus readouts it’s published thus far, he said. Speaking to the data on protection afforded by Beyfortus through six months ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

TORONTO, Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

Sanofi forecasts Beyfortus sales for the fourth quarter to be similar to the third quarter. Price Action: SNY stock is up 2.82% at $53.52 during the premarket session at the last check on Friday.

Wide-moat Sanofi reported better-than-expected third-quarter earnings driven by strong performance of the RSV prophylaxis drug Beyfortus and influenza vaccines. We've increased our fair value ...